World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
29781
World Ranking
13583
National Ranking
559

Yves Fradet publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Yves Fradet sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 512 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Yves Fradet D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Yves Fradet sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Yves Fradet is affiliated with Université Laval in Canada and has a research portfolio comprising extensive work in medicine and biochemistry, genetics, and molecular biology. Their studies focus primarily on surgery, oncology, pulmonary and respiratory medicine, molecular biology, and cancer research.

The researcher has contributed notably to topics such as bladder and urothelial cancer treatments, cancer immunotherapy and biomarkers, urinary and genital oncology studies, prostate cancer treatment and research, cancer, lipids, and metabolism, prostate cancer diagnosis and treatment, and metabolomics and mass spectrometry studies.

Fradet's work has appeared frequently in prominent scientific journals, including the Journal of Clinical Oncology, Annals of Oncology, Canadian Urological Association Journal, Cancer Immunology Research, and The Journal of Urology. These venues are the primary platforms for their contributions to the academic community.

Their research collaborations involve frequent co-authors, notably Alain Bergeron, Vincent Fradet, Louis Lacombe, Paul Toren, and Blanca Homet Moreno, each contributing across numerous joint publications.

Among the notable recent papers affiliated with Fradet's work are:

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota, 2022, Cancer Discovery
  • Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study, 2020, The Journal of Urology
  • Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up, 2022, Annals of Oncology

Best Publications

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

    Ina L. Deras;Sheila M.J. Aubin;Amy Blase;John R. Day

  • Genomic hallmarks of localized, non-indolent prostate cancer

    Michael Fraser;Veronica Y. Sabelnykova;Takafumi N. Yamaguchi;Lawrence E. Heisler

  • Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

    Vinata B. Lokeshwar;Tomonori Habuchi;H. Barton Grossman;William M. Murphy

  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

    Brant A. Inman;Thomas J. Sebo;Xavier Frigola;Haidong Dong

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data

    Maximilian Burger;H. Barton Grossman;Michael Droller;Joerg Schmidbauer

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

    Scott A. Tomlins;Sheila M. J. Aubin;Javed Siddiqui;Robert J. Lonigro

  • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

    M E Gleave;M Elhilali;Y Fradet;I Davis

  • A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study

    Yves Fradet;H. Barton Grossman;Leonard Gomella;Seth Lerner

  • A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder Cancer

    H. Barton Grossman;Leonard Gomella;Yves Fradet;Alvaro Morales

  • Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    Y Fradet;J Bellmunt;D J Vaughn;J L Lee

  • Urinary diversion after radical cystectomy for bladder cancer: Options, patient selection, and outcomes

    Richard K. Lee;Hassan Abol-Enein;Walter Artibani;Bernard Bochner

  • Widespread and Functional RNA Circularization in Localized Prostate Cancer

    Sujun Chen;Sujun Chen;Sujun Chen;Vincent Huang;Xin Xu;Julie Livingstone

  • Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies

    Yves Fradet;Carlos Cordon-Cardo;Timothy Thomson;Mary E. Daly

  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)

    Dana E. Rathkopf;Matthew R. Smith;Johann S. De Bono;Christopher J. Logothetis

  • Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer

    Arnulf Stenzl;Maximilian Burger;Yves Fradet;Lance A. Mynderse

  • uPM3, a new molecular urine test for the detection of prostate cancer.

    Yves Fradet;Fred Saad;Armen Aprikian;Jean Dessureault

  • Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

    Hans Martin Fritsche;Maximilian Burger;Robert S. Svatek;Claudio Jeldres

Frequent Co-Authors

Wassim Kassouf
Wassim Kassouf McGill University
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center
Pierre I. Karakiewicz
Pierre I. Karakiewicz University of Montreal
Fred Saad
Fred Saad University of Montreal
Giacomo Novara
Giacomo Novara University of Padua
Seth P. Lerner
Seth P. Lerner Baylor College of Medicine
Patrick J. Bastian
Patrick J. Bastian Ludwig-Maximilians-Universität München
Colin P. Dinney
Colin P. Dinney The University of Texas MD Anderson Cancer Center
Vincenzo Ficarra
Vincenzo Ficarra University of Messina

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers but seeking flexible study options, online degrees offer valuable pathways. Many choose programs like medical coding certification cost programs, which can provide a quick entry into medical administrative roles. The investment is often significantly lower than traditional, on-campus degrees.

Nursing is another popular online study area. If you’re considering becoming a nurse practitioner, you can explore cheapest online np programs to help minimize student debt while qualifying for advanced clinical positions. Curious about general nursing programs? Find details such as how much is online nursing school to compare expenses across accredited options.

For experienced nurses seeking leadership or educator roles, doctorate in nursing education online programs provide a flexible path toward the highest credentials in the field. Overall, online healthcare education can greatly expand access to rewarding medical careers while helping students manage costs.

Best Scientists Citing Yves Fradet

Trending Scientists

Recently Published Articles